News and Press - JDRF T1D Fund

Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development

April 06, 2022 | Boston, MA

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

April 04, 2022 | WATERTOWN, Mass.

Jaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New Investors

March 29, 2022 | LAKE FOREST, Ill.

Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial

March 15, 2022 | MONTREAL (CANADA)

Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases

February 22, 2022 | Greater Philadelphia, Pa.